A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

When the music changes, so does the dance: Time for biopharma to get in step with value-based contracting

by Joseph M. Coppola, Managing Director, Life Sciences Commercial and Market Access Practice Leader, Deloitte Consulting LLP

There is a well-known African proverb, “When the music changes, so does the dance.” I was thinking about this recently when I was a panelist on SAP’s Changing the Game in Life Sciences radio program, “Outcome-Based Pricing: Cure for An Ailing Healthcare Industry.” The moderator asked me for a quote that I felt best represented what was happening in the industry related to emerging pricing and payment models.

Read more

To ensure low-cost generic drugs, manufacturers must find equilibrium

by Faith Glazier, Principal, Deloitte Consulting LLP

Headlines and politics have been focusing quite a bit of attention on the price of pharmaceuticals – particularly generic drugs. While manufacturers of generic drugs have been effective at keeping treatment costs down, pressure to trim costs further could have the opposite effect, particularly if it leads to unprofitable products.

Generics account for the vast majority of drug sales in the US,

Read more

For biopharma, value-based competition is likely the new reality regardless of policy

by Ralph Marcello, Principal, Deloitte Consulting LLP

Click here to see the infographic

Many biopharma companies are under growing pressure from policy makers on both sides of the aisle – as well as from state and federal regulators and lawmakers – to demonstrate greater value from drug spend. While many can agree the health care system could benefit from reduced drug spending,

Read more

Early digital health innovations in treating depression

by Doug Beaudoin, Principal, Deloitte Consulting LLP

Researchers are finding some early successes in using digital health techniques to treat depression.

Depression is a global health problem: More than 300 million people struggle with clinical depression world-wide. Barriers to treatment for these patients include cost, time, stigma, and access. In many areas of behavioral health, the relationship between the patient and the therapist is seen as essential to effective care.

Read more

Value-based contracting could help biopharma share drug costs, risks

by Ralph Marcello, Principal, Deloitte Consulting LLP

Drug pricing has been under a microscope for the past several years. It was on the platform during last year’s presidential election, and is a focus for the White House, Congress, and regulators. It seems only appropriate that we spend a little time discussing drug pricing at this year’s BIO International Convention.

Scientific progress is leading to effective but sometimes expensive treatments.

Read more

Curative therapies: Can breakthrough reimbursement models break through financial barriers?

by Tom Yang, Principal, Monitor Deloitte, Deloitte Consulting, LLP

For biopharma companies, it can be far more profitable to treat a disease than cure it. The traditional business model largely relies on the delivery of chronic therapies that slow disease progression and/or alleviate symptoms for patients with serious medical conditions. But the business model for curative therapeutics is different, and runs counter to this and many other industries where a successful product commonly leads to more customers and bigger profits.

Read more